These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31718776)

  • 1. Editorial overview: Engineering cellular resistance towards the HIV cure.
    Liang C; Berkhout B
    Curr Opin Virol; 2019 Oct; 38():iii-v. PubMed ID: 31718776
    [No Abstract]   [Full Text] [Related]  

  • 2. Apobec3G-Based Strategies to Defeat HIV Infection.
    Ran X; Ao Z; Yao X
    Curr HIV Res; 2016; 14(3):217-24. PubMed ID: 26957196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial overview: Attrition warfare: host cell weapons against intracellular pathogens, and how the pathogens fight back.
    Stallings CL; Glickman MS
    Curr Opin Immunol; 2019 Oct; 60():vi-ix. PubMed ID: 31471114
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic and immune determinants of immune activation in HIV-exposed seronegative individuals and their role in protection against HIV infection.
    Fenizia C; Rossignol JF; Clerici M; Biasin M
    Infect Genet Evol; 2018 Dec; 66():325-334. PubMed ID: 29258786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Early Bird Catches the Worm--Can Evolution Teach us Lessons in Fighting HIV?
    Schaller T; Herold N
    Curr HIV Res; 2016; 14(3):183-210. PubMed ID: 26957195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglial Cells: The Main HIV-1 Reservoir in the Brain.
    Wallet C; De Rovere M; Van Assche J; Daouad F; De Wit S; Gautier V; Mallon PWG; Marcello A; Van Lint C; Rohr O; Schwartz C
    Front Cell Infect Microbiol; 2019; 9():362. PubMed ID: 31709195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV controllers: a genetically determined or inducible phenotype?
    Sáez-Cirión A; Pancino G
    Immunol Rev; 2013 Jul; 254(1):281-94. PubMed ID: 23772626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.
    Bennett RP; Salter JD; Smith HC
    Trends Mol Med; 2018 May; 24(5):507-520. PubMed ID: 29609878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational genomics. Targeting the host immune response to fight infection.
    Baillie JK
    Science; 2014 May; 344(6186):807-8. PubMed ID: 24855243
    [No Abstract]   [Full Text] [Related]  

  • 10. Are human Vδ2
    Mikulak J; Dieli F; Mavilio D
    EBioMedicine; 2019 May; 43():30. PubMed ID: 31072771
    [No Abstract]   [Full Text] [Related]  

  • 11. Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention.
    Shukla E; Chauhan R
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enterobacteria and host resistance to infection.
    Kang E; Crouse A; Chevallier L; Pontier SM; Alzahrani A; Silué N; Campbell-Valois FX; Montagutelli X; Gruenheid S; Malo D
    Mamm Genome; 2018 Aug; 29(7-8):558-576. PubMed ID: 29785663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating HIV-Human Interaction Networks to Unravel Pathogenic Mechanism for Drug Discovery: A Systems Biology Approach.
    Li CW; Chen BS
    Curr HIV Res; 2018; 16(1):77-95. PubMed ID: 29468972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of Latency as Part of a Cure for HIV-1.
    Rasmussen TA; Tolstrup M; Søgaard OS
    Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
    Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
    EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of engineered antibodies for HIV-1 therapy and cure.
    Grobben M; Stuart RA; van Gils MJ
    Curr Opin Virol; 2019 Oct; 38():70-80. PubMed ID: 31421319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):68-69. PubMed ID: 29667947
    [No Abstract]   [Full Text] [Related]  

  • 19. Long Noncoding RNAs in Host-Pathogen Interactions.
    Agliano F; Rathinam VA; Medvedev AE; Vanaja SK; Vella AT
    Trends Immunol; 2019 Jun; 40(6):492-510. PubMed ID: 31053495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine networks during HIV infection: shifting the balance.
    Haddad EK; Hiscott J
    Cytokine Growth Factor Rev; 2012; 23(4-5):139-41. PubMed ID: 22766355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.